The British pharma giant said Emma Walmsley's current pay could put off candidates for her eventual successor.

For GSK CEO Emma Walmsley, there was good news and bad news in the company’s annual report. | For GSK CEO Emma Walmsley, there was good news and bad news in the company’s annual report. While it ...

One of the lowest paid CEOs in pharma—and one of the only woman leading a top-tier giant—is set to receive up to $27.2 ...

Eli Lilly CEO Dave Ricks made $114 million last year, according to a new proxy statement, a rare instance of a health ...

GlaxoSmithKline (GSK) appears to be focusing more on finding a new CEO than any large M&A deals after last year's $20 billion asset swap with Novartis, according to a briefing following strong Q1 ...

Allergan's market cap: $48 billion GlaxoSmithKline CEO Emma Walmsley $7,662,210 Emma Walmsley has led the British drug giant GlaxoSmithKline for about two years, overseeing a time of transition ...

For Big Pharma CEOs, compensation can swing drastically year to year — from base salary to bonus incentives to stock options ...

GlaxoSmithKline (GSK) has appointed its consumer health leader, Emma Walmsley, to take over as CEO when Sir Andrew Witty retires next year. Walmsley has a background in marketing, and joined GSK ...

Speaking at the CEO Times Summit in London, Walmsley highlights the U.K. pharmaceutical company's refocused R&D strategy, with investments concentrated in the U.K., U.S., and Europe. GSK ...